New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
Adult
Aged
B7-H1 Antigen
/ biosynthesis
Epstein-Barr Virus Infections
/ complications
Female
Herpesvirus 4, Human
Humans
Immunophenotyping
Inflammation
/ genetics
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Microsatellite Instability
Middle Aged
Stomach Neoplasms
/ genetics
T-Lymphocytes
/ immunology
Transcriptome
Tumor Microenvironment
/ genetics
Epstein–Barr virus (EBV)
Gastric cancer
Gene expression profiling
Microsatellite instability (MSI)
PD-L1
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
16
04
2018
accepted:
09
05
2018
pubmed:
21
5
2018
medline:
16
4
2019
entrez:
21
5
2018
Statut:
ppublish
Résumé
Gastric cancer with lymphoid stroma (GCLS) is characterized by prominent stromal infiltration of T-lymphocytes. The aim of this study was to investigate GCLS biology through analysis of clinicopathological features, EBV infection, microsatellite instability (MSI), immune gene-expression profiling and PD-L1 status in neoplastic cells and tumor immune microenvironment. Twenty-four GCLSs were analyzed by RNA in situ hybridization for EBV (EBER), PCR/fragment analysis for MSI, immunohistochemistry (PD-L1, cytokeratin, CD3, CD8), co-immunofluorescence (CK/PD-L1, CD68/PD-L1), NanoString gene-expression assay for immune-related genes and PD-L1 copy number alterations. CD3+ and CD8+ T-cell densities were calculated by digital analysis. Fifty-four non-GCLSs were used as control group. GCLSs displayed distinctive clinicopathological features, such as lower pTNM stage (p = 0.02) and better overall survival (p = 0.01). EBV+ or MSI-high phenotype was found in 66.7 and 16.7% cases, respectively. GCLSs harbored a cytotoxic T-cell-inflamed profile, particularly at the invasive front of tumors (p < 0.01) and in EBV+ cases (p = 0.01). EBV+ GCLSs, when compared to EBV- GCLSs, showed higher mRNA expression of genes related to Th1/cytotoxic and immunosuppressive biomarkers. PD-L1 protein expression, observed in neoplastic and immune stromal cells (33.3 and 91.7%, respectively), and PD-L1 amplification (18.8%) were restricted to EBV+/MSI-high tumors and correlated with high values of PD-L1 mRNA expression. This study shows that GCLS has a distinctive clinico-pathological and molecular profile. Furthermore, through an in-depth study of tumor immune microenvironment-by digital analysis and mRNA expression profiling-it highlights the role of EBV infection in promoting an inflamed tumor microenvironment, with putative therapeutic implications.
Sections du résumé
BACKGROUND
Gastric cancer with lymphoid stroma (GCLS) is characterized by prominent stromal infiltration of T-lymphocytes. The aim of this study was to investigate GCLS biology through analysis of clinicopathological features, EBV infection, microsatellite instability (MSI), immune gene-expression profiling and PD-L1 status in neoplastic cells and tumor immune microenvironment.
METHODS
Twenty-four GCLSs were analyzed by RNA in situ hybridization for EBV (EBER), PCR/fragment analysis for MSI, immunohistochemistry (PD-L1, cytokeratin, CD3, CD8), co-immunofluorescence (CK/PD-L1, CD68/PD-L1), NanoString gene-expression assay for immune-related genes and PD-L1 copy number alterations. CD3+ and CD8+ T-cell densities were calculated by digital analysis. Fifty-four non-GCLSs were used as control group.
RESULTS
GCLSs displayed distinctive clinicopathological features, such as lower pTNM stage (p = 0.02) and better overall survival (p = 0.01). EBV+ or MSI-high phenotype was found in 66.7 and 16.7% cases, respectively. GCLSs harbored a cytotoxic T-cell-inflamed profile, particularly at the invasive front of tumors (p < 0.01) and in EBV+ cases (p = 0.01). EBV+ GCLSs, when compared to EBV- GCLSs, showed higher mRNA expression of genes related to Th1/cytotoxic and immunosuppressive biomarkers. PD-L1 protein expression, observed in neoplastic and immune stromal cells (33.3 and 91.7%, respectively), and PD-L1 amplification (18.8%) were restricted to EBV+/MSI-high tumors and correlated with high values of PD-L1 mRNA expression.
CONCLUSIONS
This study shows that GCLS has a distinctive clinico-pathological and molecular profile. Furthermore, through an in-depth study of tumor immune microenvironment-by digital analysis and mRNA expression profiling-it highlights the role of EBV infection in promoting an inflamed tumor microenvironment, with putative therapeutic implications.
Identifiants
pubmed: 29779068
doi: 10.1007/s10120-018-0836-8
pii: 10.1007/s10120-018-0836-8
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77-90Références
Hepatogastroenterology. 1999 Mar-Apr;46(26):1214-9
pubmed: 10370694
Histopathology. 2000 Oct;37(4):309-15
pubmed: 11012737
Virchows Arch. 2001 Aug;439(2):158-69
pubmed: 11561756
Mod Pathol. 2003 Jul;16(7):641-51
pubmed: 12861059
Histopathology. 2004 Nov;45(5):485-92
pubmed: 15500652
Virchows Arch. 2009 Sep;455(3):197-211
pubmed: 19672623
Clin Cancer Res. 2010 Mar 1;16(5):1662-72
pubmed: 20179239
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Gastroenterology. 2011 Aug;141(2):476-85, 485.e1-11
pubmed: 21684283
Pathol Res Pract. 2011 Sep 15;207(9):529-37
pubmed: 21944426
Hum Mutat. 2012 Mar;33(3):480-4
pubmed: 22190470
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Hum Genet. 2013 Jun;132(6):641-8
pubmed: 23430453
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
Virchows Arch. 2014 Mar;464(3):367-78
pubmed: 24487788
Gastric Cancer. 2015 Apr;18(2):246-55
pubmed: 24771002
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
J Surg Res. 2015 Apr;194(2):458-63
pubmed: 25592274
Int J Oncol. 2015 Apr;46(4):1421-34
pubmed: 25633561
Clin Gastroenterol Hepatol. 2015 Oct;13(10):1738-1744.e2
pubmed: 25912839
Gut. 2017 May;66(5):794-801
pubmed: 26801886
Hum Pathol. 2016 Jul;53:25-34
pubmed: 26980034
Oncotarget. 2016 Apr 26;7(17):24269-83
pubmed: 27009855
Mod Pathol. 2016 Jul;29(7):772-84
pubmed: 27032689
Eur J Cancer. 2016 May;59:160-170
pubmed: 27039171
Oncotarget. 2016 May 31;7(22):32925-32
pubmed: 27147580
Lancet Oncol. 2016 Jun;17(6):717-726
pubmed: 27157491
Hum Pathol. 2016 Sep;55:182-9
pubmed: 27260946
Nature. 2016 May 23;534(7607):402-6
pubmed: 27281199
Am J Surg Pathol. 2016 Nov;40(11):1496-1506
pubmed: 27465786
Gastric Cancer. 2017 May;20(3):407-415
pubmed: 27629881
Mol Oncol. 2016 Dec;10(10):1551-1558
pubmed: 27720576
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
ESMO Open. 2016 Feb 17;1(1):e000009
pubmed: 27843583
Mod Pathol. 2017 Mar;30(3):427-439
pubmed: 27934877
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Oncoimmunology. 2016 Nov 22;6(1):e1249558
pubmed: 28197365
J Surg Res. 2017 Apr;210:159-168
pubmed: 28457323
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Clin Cancer Res. 2017 Jul 26;:
pubmed: 28747339
Eur J Cancer. 2017 Nov;86:305-317
pubmed: 29065378
Oncoimmunology. 2017 Aug 10;6(11):e1356150
pubmed: 29147610
Cancer. 1976 Jul;38(1):232-43
pubmed: 947518